Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Sep 10, 2024 7:45pm
178 Views
Post# 36217712

Regarding the os Data

Regarding the os Data Suggesting. That they have it & are sitting on is misinformed , wrong & missleading.
first, the dates do indicate updates soon.
required for full public disclosure is analysis of the data & completion of the data.
The FDA monitors the decemination of data. Meaning companies can't just sit on it.
Assuming we have full results, based on orriginal trial start & end dates?
I know, it is a hard & complicated process to understand.....but.
All of the results rely on people.
That being cancer patients, who may or may not be improving.
The " events" in some cases are end of life.
so , unless you know all of the trial paitents personally it is impossible to determine the status of the MBc O.S. Data.
please stop claiming opinions as if they are factual.
the additional ohase 2 trial has nothing directly to do with scheduling of in plac3 phase 2 trials.
meaning, it will not slow progress.
it can however expand the opportunities.


<< Previous
Bullboard Posts
Next >>